Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
33.21
+0.07 (0.21%)
Dec 20, 2024, 4:00 PM EST - Market closed
Apellis Pharmaceuticals Employees
As of December 31, 2023, Apellis Pharmaceuticals had 706 total employees, including 702 full-time and 4 part-time employees. The number of employees decreased by 61 or -7.95% compared to the previous year.
Employees
706
Change (1Y)
-61
Growth (1Y)
-7.95%
Revenue / Employee
$1,013,054
Profits / Employee
-$354,251
Market Cap
4.13B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Integer Holdings | 10,500 |
Haemonetics | 3,657 |
Ultragenyx Pharmaceutical | 1,276 |
PROCEPT BioRobotics | 626 |
ADMA Biologics | 624 |
Prestige Consumer Healthcare | 570 |
Axsome Therapeutics | 545 |
TG Therapeutics | 264 |
APLS News
- 15 days ago - Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN - GlobeNewsWire
- 2 months ago - Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch - Benzinga
- 2 months ago - Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade) - Seeking Alpha
- 2 months ago - Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewsWire